This comprehensive report analyses recent updates to the company's platform technology and key assets, with a deep dive into the HER2+ breast cancer vaccine candidate ES2B-C001. It provides an assessment of the company's cash position and an updated sum-of-the-parts valuation. Pareto revised its price target to SEK 9.00 per share, with a “Buy” rating. The research report is available on the Analyst Reports page of ExpreS²ion’s investor website.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB